STRATEC Biomedical AG / Key word(s): Quarter Results/Interim Report
STRATEC reports on first half of 2015
Birkenfeld, July 23, 2015
STRATEC Biomedical AG, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard, TecDAX) today announced its results for the period from January 1, 2015 to June 30, 2015 upon the publication of its Interim Report as of June 30, 2015.
bps = basis points
* 2014 figure adjusted to exclude a one-off negative item resulting from the recognition in the first quarter of expenses for the remaining years of the term of a management board contract for a retired member of the Board of Management. Unadjusted EBIT for the first half of 2014 amounted to EUR 10.3 million; the corresponding EBIT margin amounted to 14.9%, consolidated net income to EUR 8.9 million and earnings per share to EUR 0.76. The actual amount of the aforementioned expense item may differ at the time of payment from the amounts presented here.
Free cash flow in the first half declined to EUR 9.4 million due to reporting date-related increases in customer receivables and a higher tax expenses. Cash and cash equivalents rose to EUR 49.1 million at the reporting date on June 30, 2015. The equity ratio amounts to 78.4%.
Annual General Meeting and dividend proposal
Development in personnel
Projects and other developments
The expansion in production and development capacities is set to play a major role in the company's future growth strategy. The move into the new buildings at the Romanian location and in Switzerland is scheduled to take place in the first half of 2016.
Financial forecast remains valid
The targets set out in our financial forecast first communicated in July 2013, which provide for average annual sales growth of eight to twelve percent through to 2017 accompanied by increasing profitability, remain valid. We expect figures to fall below or exceed this range in individual years.
As well as pursuing the opportunities offered by organic growth, STRATEC is increasingly reviewing external opportunities which would enable the company to generate faster growth in key areas or access new niche markets. All activities serve to broaden the share of the value chain we can offer to our customers. One key priority is to avoid entering into any competitive situation with existing or potential partners.
Interim report as of June 30, 2015
Further information can be obtained from:
2015-07-23 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
|Company:||STRATEC Biomedical AG|
|Phone:||+49 (0)7082 7916 0|
|Fax:||+49 (0)7082 7916 999|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart|
|End of News||DGAP News-Service|